You searched for lung cancer | Page 90 of 153

Agilent to Acquire Resolution Bioscience

The acquisition of Resolution Bioscience complements and expands Agilent’s capabilities in NGS-based cancer diagnostics.

Developing technology ushers in a new era in precision oncology.

The FDA has approved two comprehensive genomic profiling liquid biopsy tests for use in supporting doctors with their treatment decision-making.

The transaction includes proprietary IP and technology for blood-based immune therapy monitoring and for transplant rejection testing.

The group claim will also enable the test to be used as a CDx for any future approved EGFR TKI therapies targeting the same mutations.